Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.07 USD | +0.12% | -2.83% | -8.12% |
05-16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
05-15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
Sales 2024 | 4,264B 27.16B 37.27B | Sales 2025 * | 4,108B 26.16B 35.91B | Capitalization | 6,486B 41.31B 56.7B |
---|---|---|---|---|---|
Net income 2024 | 144B 918M 1.26B | Net income 2025 * | 136B 864M 1.19B | EV / Sales 2024 | 1.54 x |
Net Debt 2024 * | 3,771B 24.02B 32.96B | Net Debt 2025 * | 4,204B 26.78B 36.75B | EV / Sales 2025 * | 2.6 x |
P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
45.8
x | Employees | 49,095 |
Yield 2024 * |
4.55% | Yield 2025 * |
4.61% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 day | +0.12% | ||
1 week | -2.83% | ||
Current month | -0.60% | ||
1 month | -2.43% | ||
3 months | -11.10% | ||
6 months | -6.51% | ||
Current year | -8.12% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 13.07 | -0.22% | 824 |
24-05-22 | 13.1 | -0.83% | 2,617 |
24-05-21 | 13.21 | -0.54% | 1,342 |
24-05-20 | 13.28 | +0.08% | 2,782 |
24-05-17 | 13.27 | -0.52% | 253 |
Delayed Quote London S.E., May 23, 2024 at 10:28 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.69% | 723B | |
+34.28% | 595B | |
-4.49% | 369B | |
+20.24% | 332B | |
+2.12% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
-0.35% | 168B |
- Stock Market
- Equities
- 4502 Stock
- 0A87 Stock